We present the subanalysis of the Greek cohort of the Extended Forsteo Observational Study (ExFOS), a multicenter, non-interventional, prospective, observational study evaluating the effect of teriparatide on fractures, back pain (BP), health-related quality of life (HR-QoL), and safety and compliance, in patients with osteoporosis treated for up to 24 months, with a post-treatment follow-up of at least 18 months.
A total of 439 osteoporotic patients (92.2% female) were enrolled in Greece. New or worsened fractures, based on their physicians’ assessment, as well as patients’ self-assessment of HR-QoL and BP, compliance, and safety profile, were captured by validated questionnaires.
In the ExFOS Greek cohort, fracture rates were low and mean bone mineral density (BMD) was numerically improved. Compliance with teriparatide remained high throughout the study, with 81.5% of subjects completing treatment. Only 0.7% of patients reported discontinuation due to adverse effects. A sustainable improvement in patient-perceived BP and HRQoL throughout treatment and follow-up was similar to that achieved by the European Forsteo Observational Study (EFOS). A lower than expected percentage of patients using antiresorptives following teriparatide was recorded.
ExFOS reproduces the outcomes of EFOS, with a 6.5-year time interval between studies, in comparable cohorts of osteoporotic patients. Data should be interpreted in the context of observational study data collection, although summary statistics computed at each time point may overstate drug effect.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Dempster DW, Zhou H, Recker RR et al (2012) Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab 97(8):2799–2808
Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246–256
Murad MH, Drake MT, Mullan RJ et al (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1−34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 10 344(19):1434–1441
Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230–240
Stroup J, Kane MP, Abu-Baker AM (2008) Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 15 65(6):532–539
Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ (2016) Teriparatide for osteoporosis: importance of the full course. Osteoporosis Int 27(8):2395–2410
Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 11 312(7040):1215–1218
Cooper C, Jakob F, Chinn C et al (2008) Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporosis Int 19(4):493–501
Silverman S, Miller P, Sebba A et al (2013) The direct assessment of nonvertebral fractures in community experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporosis Int 24(8):2309–2317
Fahrleitner-Pammer A, Langdahl BL, Marin F et al (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporosis Int 22(10):2709–2719
Ljunggren O, Benhamou CL, Dekker J et al (2014) Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS). Curr Med Res Opin 30(8):1607–1616
Langdahl BL, Ljunggren O, Benhamou CL et al (2016) Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-month results from the Extended Forsteo Observational Study (ExFOS). Calcif Tissue Int 99(3):259–271
Napoli N, Langdahl BL, Ljunggren O et al (2018) Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo(R) Observational Study (ExFOS). Calcif Tissue Int 16. https://doi.org/10.1007/s00223-018-0437-x
Aloumanis K, Karras D, Drossinos V, Korelis E, Polydorakis A (2011) Fracture incidence, quality of life, and back pain during 18-months treatment with teriparatide in Greek postmenopausal women with osteoporosis: results from the European Forsteo Observational Study. J Osteoporos 510398
Aloumanis K, Drossinos V, Trikka D, Karras D (2012) The European Forsteo Observational Study (EFOS). 18-month follow-up of Greek women completing teriparatide treatment for osteoporosis. Archives of Hellenic. Medicine 29(4):454–460 [Greek]
Aloumanis K, Kapetanos G, Bartzis N, Drossinos V (2015) Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS). BMC Musculoskelet Disord 05(16):136
Brooks R (1996) EuroQol: the current state of play. Health policy 37(1):53–72
Aloumanis K, Drossinos V, Hondrelis J, Disch D (2018) Treatment outcomes after teriparatide use in Greece: country subanalysis of the EFOS and ExFOS combined Observational Studies WCO-IOF-ESCEO-2018 2018; abstr. P428. Osteoporos Int 29(1)
Prince R, Sipos A, Hossain A et al (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20(9):1507–1513
Eastell R, Nickelsen T, Marin F et al (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24(4):726–736
Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94(8):2915–2921
Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-follow-up). Bone 98:54–58
Hadji P, Zanchetta JR, Russo L et al (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis Int 23(8):2141–2150
Ohtori S, Akazawa T, Murata Y et al (2010) Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 17(2):209–213
We extend our thanks to the Greek ExFOS Study Group: Adam A, Alexandridis T, Athanasakopoulos P, Dimopoulos N, Dionyssiotis Y, Georgountzos A, Giannadakis P, Gkouvas G, Kapetanos G, Kaplanoglou T, Karagiannis A, Kleisiounis A, Kokkoris P, Kosmidis C, Kossyvakis K, Krallis N, Matsouka A, Matzaroglou C, Meleteas E, Milonas C, Mpintas S, Papaioannou N, Papazisis Z, Repousis AP, Savvidis M, Temekonidis T, Trovas G, Tsakiri V, Tzoitou M, Tzoutzopoulos A, Vandoros G, Ziambaras K.
The authors wish to thank Christopher Jeremy Child PhD, Research Advisor—Endocrinology for editing the manuscript.
KA and VD are employees of Pharmaserve-Lilly SACI.
About this article
Cite this article
Aloumanis, K., Kapetanos, G., Alexandridis, T. et al. Conducting an observational study during an economic crisis: analysis of the treatment and follow-up phase of Greek patients participating in the ExFOS study. Hormones 17, 531–540 (2018). https://doi.org/10.1007/s42000-018-0077-6
- Back pain
- Quality of life